Introduction: The treatment of type 2 diabetes
only effectively treat hyperglycemia, but are also weight neutral or promote weight loss. In most clinical situations after diagnosis, patients are advised to adopt lifestyle changes and metformin is initiated to help control blood glucose levels. However, metformin may not be tolerated, or may not be sufficient for those with higher glucose levels at diagnosis. Even among those who have initial success with metformin, the majority eventually require one or more additional agents to achieve their treatment goals. Because T2DM is a progressive disease, the requirement for combination treatment escalates over time, driving the need for therapies with complementary mechanisms of action. Methods and Results: Online public resources were searched using ''empagliflozin'', identifying 32 articles in PubMed, and 12 abstracts presented at the 2013 American Diabetes Association meeting. Peer-reviewed articles and abstracts describing preclinical studies and clinical trials were retrieved, and relevant publications included in this review. Trials registered on clinicaltrials.gov were searched for ongoing empagliflozin studies. Conclusion: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are of great interest since they provide a novel, insulin-independent mechanism of action. The SGLT2 inhibitor empagliflozin has demonstrated promising pharmacodynamic and pharmacokinetic properties.
In clinical trials, empagliflozin has demonstrated a good efficacy and safety profile in a broad range of patients with T2DM, and appears to be an attractive adjunct therapeutic option for the treatment of T2DM. Ongoing trials, including patients with T2DM and comorbidities such as [1] . In the US, as elsewhere, this increase is generally seen in parallel with the rise in the prevalence of obesity, which is now at epidemic proportions [1, 2] . The total economic burden associated with diabetes treatment and lost productivity is substantial; in the US alone, these costs have been calculated at 245 billion USD for 2012 [3] .
After diagnosis, treatment for T2DM is initially focused on lifestyle management and includes changes in dietary choices, consumption patterns, and the institution of exercise regimens to reduce weight, enhance insulin sensitivity, and lower blood glucose levels [4] . If these strategies do not achieve the desired goals for blood glucose [or if at diagnosis a patient's glycosylated hemoglobin (HbA1c) level is [7.5%] , then guidelines recommend pharmacotherapy at diagnosis [4] . Metformin is recommended as initial therapy with addition of sulfonylureas, thiazolidinediones, dipeptidyl peptidase (DPP)-4 inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodiumglucose co-transporter 2 (SGLT2) inhibitors, or insulin as needed [4] . These agents have different mechanisms of action, and different effects on insulin resistance, insulin secretion, and weight. Therefore, the risk/benefit ratio of each drug, or drug combination, needs consideration in light of therapeutic goals and potential safety concerns for individual patients [4] .
Of these different classes of anti-diabetes drugs, the SGLT2 inhibitors are the newest. These agents help regulate blood glucose levels by blocking the reuptake of filtered glucose in the proximal tubule, leading to significant excretion of glucose via the urine, which is a novel and insulin-independent approach ( 
Discovery and Brief History of SGLT Inhibitors
For over a century, a naturally occurring botanical glucoside has been known to contribute to glucosuria in animals and humans [6] . This active compound was eventually identified as phlorizin and it was established that increased glucose excretion could help regulate blood glucose levels [6] . Early studies showed that phlorizin inhibited the transport of glucose in a variety of tissues, including the kidney and small intestine [7, 8] .
Further investigation identified phlorizin as a competitive inhibitor of the SGLT1 and SGLT2 proteins, which are membrane-embedded proteins responsible for reabsorption of glucose from the glomerular filtrate in the kidney. SGLT1 is also found in the small intestine, where it is responsible for absorption of glucose and galactose.
In a diabetic rat model, phlorizin treatment increased glucose concentration in urine, and normalized plasma glucose levels in the absence of hypoglycemia, in both fasting and fed states [9] . Phlorizin also improved insulin sensitivity [9] . While these properties made phlorizin very interesting, it was ultimately unsuitable for Fig. 1 Key agents and sites of action for type 2 diabetes mellitus drugs. DPP dipeptidyl peptidase, GI gastrointestinal, GIP gastric inhibitory polypeptide, GLP glucagon-like peptide, SGLT2 sodium-glucose co-transporter 2 clinical development for several reasons. Firstly, phlorizin is broken down in the gastrointestinal tract, and must thus be administered intravenously; secondly, the active metabolite, phloretin, is a potent inhibitor of facilitative glucose transporters; and thirdly, phlorizin is associated with frequent gastrointestinal adverse events (AEs) including diarrhea and dehydration [10] . Although these events are usually attributed to phlorizin's limited selectivity for SGLT2 over SGLT1 (and consequent presence of unabsorbed glucose and galactose in the large intestine), early studies with dual SGLT1/2 inhibitors suggest SGLT1 inhibition is not inevitably associated with gastrointestinal AEs [11] . Nevertheless, it was clear that phlorizin was not suitable for further development, but did serve as a basis for the identification of inhibitors with improved safety and tolerability profiles.
Empagliflozin Pharmacological Characteristics and Mechanistic Studies
Extensive drug discovery and development studies in vitro identified BI 10773 Fig. 2 ) as a potent and selective competitive inhibitor of the SGLT2 protein.
Empagliflozin is structurally related to phlorizin; however, while phlorizin is an O-glucoside and thus susceptible to degradation by b-glucosidase in the gastrointestinal tract, empagliflozin is a C-glucoside, and the carboncarbon bond between the glucose and aglycone moieties makes it resistant to gastrointestinal degradation, allowing oral administration [5] . The pharmacokinetic and pharmacodynamic (PK/PD) attributes of empagliflozin have been extensively tested in vitro and in vivo, and were also analyzed [13] . Taken together, these studies demonstrated that empagliflozin is a Fig. 2 Chemical structure of empagliflozin Subsequent in vivo pharmacological studies confirmed that empagliflozin lowered blood glucose levels and improved glycemic control in diabetic rodent models, with dose-dependent increases in urinary glucose excretion (UGE) [14] . In addition, 5 weeks of empagliflozin treatment reduced HbA1c levels by 0.3% and 1.1% with 1 or 3 mg/kg, respectively, compared with an increase of 1.1% in vehicle-treated animals. Improved insulin sensitivity was also recorded with empagliflozin [14] .
The metabolic response to empagliflozin has been studied in patients with T2DM [15] .
As predicted from the theory of glucotoxicity, reduction of blood glucose with empagliflozin was associated with improvements in measures of insulin resistance and beta-cell function. The investigators also observed an unexpected increase in endogenous glucose production, possibly resulting from an increase in plasma glucagon levels [15] . It has been suggested that combination therapy with an agent that inhibits glucagon by increasing incretins (a GLP-1 mimetic or DPP-4 inhibitor) may give synergistic effects for the treatment of hyperglycemia, but this work is still at early stages, and additional studies are needed [16] . [17] . The amounts of glucose excreted in the urine were similar under fed and fasted conditions, indicating food had no clinically relevant effects on drug absorption. In these healthy volunteers, empagliflozin had a good safety profile and was well tolerated: reported AEs included headaches, nervous system and gastrointestinal disorders; all were reported at similar frequencies in empagliflozin and placebo-treated subjects, and none were dose-dependent. There was one report of hypoglycemia, which was observed 3 h after an oral glucose tolerance test. Since the glucose levels showed mild hypoglycemia (53 mg/dL), it was considered to be reactive hypoglycemia, and therefore not related to study drug [17] .
Similar results were seen in another Phase I study of empagliflozin doses ranging from 1 to 100 mg in 48 healthy Japanese men [18] .
Empagliflozin was rapidly absorbed in these subjects, with a t max of 1.25-2.50 h, after which plasma concentrations declined with classic biphasic kinetics. Empagliflozin exposures were proportional to doses studied. At the highest doses tested (100 mg), mean UGE was approximately 74 g and UGE was dosedependent. Empagliflozin was again well tolerated, with no reports of hypoglycemia in any of the subjects [18] .
Following these results in healthy volunteers, a study of empagliflozin safety, tolerability, and PK/PD was conducted over 28 days in patients with T2DM [19] . Seventyeight patients received placebo (n = 16) or empagliflozin once-daily at one of three doses: 10 mg (n = 16), 25 mg (n = 16), or 100 mg (n = 30). Twice as many patients were randomized to the 100-mg safety arm of this study to assess the safety of this high dose of empagliflozin.
Plasma concentrations of empagliflozin were dose-dependent over the full range of doses (10-100 mg) and linear PK were observed [19] . By Day 1, UGE rose from baseline to 74, 90, and 81 g with increasing doses of empagliflozin (10, 25 , and 100 mg, respectively). Elevated UGE continued throughout the 28 days of empagliflozin treatment, while virtually no change in UGE was observed with placebo over the same timeframe [19] . Mean daily plasma glucose and fasting plasma glucose (FPG) levels were significantly reduced from baseline in the empagliflozin groups compared with the placebo group [19] . The incidence of AEs was similar, with 50.0, 56.3, and 66.7% of patients in the empagliflozin 10-mg, 25-mg, and 100-mg groups, respectively, experiencing at least one AE versus 62.5% with placebo. The most commonly reported AEs were pollakiuria (10.3%), nasopharyngitis (9.0%), constipation (9.0%), and headache (7.7%) [19] . This suggests that while empagliflozin may be used without dose adjustments in patients with any degree of renal impairment, reductions in plasma glucose levels would be predicted to be less clinically meaningful for those with severe renal impairment [20] . A related open-label clinical trial, also using a matched controls with normal hepatic function [21] . Use of SGLT2 inhibitors in patients with impaired hepatic function has been an area of potential concern following a case of liver toxicity with dapagliflozin, although after longer follow-up the case was re-classified as auto-immune hepatitis rather than druginduced liver injury, and data from additional exposure to dapagliflozin have been reassuring [22] . In the empagliflozin study, the drug was rapidly absorbed and after achieving peak concentrations, the expected biphasic decline in plasma drug concentrations was observed [21] . PK parameters were mildly elevated, but were less than twofold the values in patients with normal hepatic function. While ongoing vigilance is always prudent, the study investigators concluded there is no need for adjustment of empagliflozin doses in patients with hepatic impairment [21] .
Empagliflozin: Coadministration with Other Drugs and Cardiac Safety
Patients with T2DM vary widely in age and often have significant comorbidities, including advanced cardiovascular disease; therefore, this patient population often is receiving several medications concurrently in addition to other anti-diabetes drugs [23] . [28] . A number of drugs are known to prolong the cardiac QT interval, which can lead to lifethreatening arrhythmias in treated patients [29] . To assess the cardiac safety of empagliflozin, 30 volunteers with a mean age of 35 years were randomized to a double-blind, placebo-controlled study of single doses of 
Renal impairment study [20] Mild (n = 9) 118.2% (96. [32] .
The groups had similar rates of AEs, at 32.9% for the placebo group and 29.1% across the empagliflozin groups. Few differences between groups were observed for the most common AEs reported with empagliflozin; these were pollakiuria (3.3% vs. 0% for placebo), thirst (3.3% vs. 0% for placebo), and nasopharyngitis (2.0% vs. 1.2% for placebo) [32] . There were AEs considered consistent with urinary tract infections (UTIs) in 4/244 patients (1.6%) on empagliflozin and 1/82 patients (1.2%) on placebo. Genital infections were reported in five patients (2%) on empagliflozin versus none on placebo. No patients discontinued due to UTIs or genital infections [32] .
A sitagliptin patients. Rates of hypoglycemia were \1% in all treatment groups [34] .
Laboratory measurements included serum lipids and plasma uric acid concentrations (Tables 6, 7 ). Of note, empagliflozin appeared to be associated with improvements in uric acid compared with placebo. In addition, compared with placebo, high-density lipoprotein (HDL)-cholesterol increased significantly from baseline in patients treated with empagliflozin 10 or 25 mg, but levels of total cholesterol, lowdensity lipoprotein (LDL)-cholesterol, or triglycerides did not change [34] .
The safety and efficacy of empagliflozin as add-on therapy in patients with T2DM receiving metformin with or without a sulfonylurea was assessed in a randomized, double-blind Phase III trial; two sub-studies were defined by the patients' background medication at screening. In the first part of the study, patients on metformin only were randomized to 24 weeks of double-blind treatment with either empagliflozin 10 mg (n = 217) or 25 mg (n = 213) once daily or placebo (n = 207) [38] . As with the previous trial, patients with HbA1c[10% at screening were not randomized, and instead were included in an open-label empagliflozin 25-mg arm (n = 69). [38] . The empagliflozin groups also had significant reductions in systolic blood pressure, with mean changes of -4.5 ± 0.7 mmHg in the 10-mg group and -5.2 ± 0.7 mmHg in the 25-mg group.
For the group of patients with very high HbA1c at screening, who were assigned openlabel empagliflozin 25 mg in addition to their background metformin, HbA1c fell by a mean ± standard error (SE) of -3.2 ± 0.2% from a baseline mean of 11.1 ± 0.2%. Improvement was also seen in FPG, with a mean ± SE reduction of -3.02 ± 0.57 mmol/L, from a baseline mean of 11.30 ± 0.43 mmol/L. The group also had reductions from baseline in body weight (mean ± SE -1.91 ± 0.59 kg) and systolic blood pressure (mean ± SE -2.4 ± 1.6). In this trial, AEs were reported by 57.1%, 49.5%, and 58.7% of patients on empagliflozin 10 mg, empagliflozin 25 mg, and placebo, respectively. Hypoglycemia (defined as plasma glucose B70 mg/dL, and/or requiring assistance) was reported in very low proportions of patients (1.8% in the empagliflozin 10-mg arm, 1.4% in the empagliflozin 25-mg arm, and 0.5% in the placebo arm), and none of the cases required assistance [38] . AEs consistent with UTIs were reported in low proportions across the treatment arms (5.1%, 5.6%, and 4.9% in the empagliflozin 10-mg, 25-mg, and placebo arms, respectively). Rates of AEs associated with genital infection were also low with empagliflozin, but appeared more frequent than with placebo (3.7% and 4.7% in the 10-mg and 25-mg empagliflozin arms vs. none in patients receiving placebo) [38] .
In the second part of the study, patients with HbA1c inadequately controlled on metformin and a sulfonylurea were randomized to add on once-daily empagliflozin 10 mg (n = 225), empagliflozin 25 mg (n = 216), or placebo (n = 225) for 24 weeks [35] . Improvements were seen in glycemic control, with reductions in HbA1c levels after 24 weeks being significantly greater in the empagliflozintreated groups, as were reductions in FPG and body weight, as shown in Tables 3, 4 , and 5 [35] .
Patients were more likely to achieve HbA1c\7.0% with empagliflozin, with 26.3% of the empagliflozin 10-mg group reaching this goal (odds ratio vs. placebo 3.85; 95% CI 2.17, 6.85; p\0.001) and 32.2% in the empagliflozin (Table 5) were consistent with earlier reports, with significant differences in the adjusted means for empagliflozin versus placebo [35] . AEs were reported at similar proportions across treatment groups, at 67.9% in the empagliflozin 10-mg group, 64.1% in the empagliflozin 25-mg group, and 62.7% in the placebo group [35] . Events consistent with UTIs were reported in 10.3% and 8.3% of the empagliflozin 10-mg and 25-mg groups, respectively, versus 8.0% of the placebo group, while events consistent with genital infections were reported in 2.7% and 2.3% of the respective empagliflozin groups versus 0.9% of the placebo group [35] . For LDL-cholesterol and triglycerides, there were no significant differences compared with placebo, while there was a small increase in HDL-cholesterol (Table 6 ). In the randomized empagliflozin groups, there were small decreases in uric acid ( Table 7) .
The third Phase III trial published is a randomized, double-blind, placebo-controlled trial that examined the efficacy and safety of empagliflozin in patients with T2DM who were on pioglitazone at screening; patients could also be receiving metformin [36] . Patients were randomized and treated with once-daily empagliflozin 10 mg (n = 165), 25 mg (n = 168), or placebo (n = 165) for 24 weeks [36] . Empagliflozin was also associated with significant reductions in body weight (Table 5) and larger proportions of patients experienced reduction of [5% of body weight (18.8% and 13.7% of patients receiving 10 mg and 25 mg of empagliflozin, compared with 5.5% of patients receiving placebo). Empagliflozin was also associated with reductions in blood pressure compared with placebo: systolic blood pressure fell by -3.9 mmHg (95% CI -6.23, -1.50; p = 0.001) with empagliflozin 10 mg and -4.7 mmHg (95% CI -7.08, -2.37; p\0.001) with empagliflozin 25 mg [36] .
In this study, as in previous studies, empagliflozin was well tolerated and the incidence of AEs was not significantly different from placebo. Similar rates of AEs were reported in all three treatment arms (67.3%, 71.4%, and 72.7% of patients in the 10-mg, 25-mg, and placebo groups, respectively). Rates of reported hypoglycemia (plasma glucose B70 mg/dL and/ or requiring assistance) were also similar across treatment arms (1.2%, 2.4%, and 1.8% of the respective groups), and no patient required assistance. The proportion of patients with AEs related to UTIs was similar across groups (17.0%, 11.9%, and 16.4% of patients on 10 mg, 25 mg, and placebo, respectively); events consistent with genital infection were seen more commonly with empagliflozin (8.5%, 3.6%, and 2.4% of patients on 10 mg, 25 mg, and placebo, respectively); however, all were mild or moderate in intensity and none led to premature study discontinuation [36] . Measurement of serum lipids showed significant increase in HDL-cholesterol in the empagliflozin 10-mg group, but a nonsignificant increase in the 25-mg group (Table 6) . No significant differences were reported for total cholesterol, LDL-cholesterol, or triglycerides in either of the empagliflozin treatment arms (Table 6 ). Again, small decreases were seen in uric acid levels with empagliflozin, of approximately the same level seen in the study of empagliflozin as add-on to metformin plus sulfonylurea (Table 7) . [42] . Japanese regulatory authorities also require a range of trials in Japanese patients, and these are underway.
Clearly, the number of clinical trials that are expected to report in the near future will provide a wealth of data on the safety and efficacy of empagliflozin treatment, to help optimize treatment regimens for individual patients.
CONCLUSIONS
Based on the evidence available to date, empagliflozin appears to have a promising pharmacologic profile. Pharmacodynamic and pharmacokinetic characteristics include: (1) very high selectivity for the SGLT2 over SGLT1
receptors, potentially minimizing off-target effects; (2) predictable pharmacokinetics, and no known drug-drug interactions with other drugs commonly prescribed for this patient population; (3) favorable pharmacodynamics, including additive control of plasma glucose levels via inhibition of reuptake in the kidney, with a well-defined dose-response relationship; (4) a good safety profile, with no increase in hypoglycemia compared with placebo; and (5) acceptable tolerability in all patient populations studied to date. The most common AEs reported to date include nasopharyngitis, UTIs, and genital tract infections. Changes in uric acid and LDL-cholesterol are of considerable interest-while the changes in uric acid appear favorable, the changes in lipid profiles have been less consistent between studies-yet it must be remembered that these values were captured as safety endpoints in the trials, and thus any potential benefit cannot be defined 
